Scarica l'app Stockscreener
33.42
0.45%
-0.15
Dopo l'orario di chiusura:
32.98
-0.44
-1.32%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CAPR Giù?
Forum
Previsione
Frazionamento azionario
Capricor Therapeutics Inc Borsa (CAPR) Ultime notizie
Is It Too Late To Consider Capricor Therapeutics (CAPR) After Strong Multi Year Share Gains? - simplywall.st
Capricor Therapeutics’ DMD Treatment Study Shows Improvement In Key Heart Function Measures - Asianet Newsable
Johnson Fistel, PLLP Investigates Claims on Behalf of - GlobeNewswire
Capricor Therapeutics (CAPR) Reveals Promising Data from Phase 3 HOPE-3 Trial - GuruFocus
Capricor earnings on deck after FDA resumes deramiocel review By Investing.com - Investing.com Nigeria
CAPR Stock In Focus: Capricor Says Phase 3 DMD Trial Shows Cardiac Improvement With Deramiocel - Stocktwits
Capricor earnings on deck after FDA resumes deramiocel review - Investing.com UK
Capricor Therapeutics Announces Late-Breaking HOPE-3 Data - GlobeNewswire
Capricor Therapeutics Hits Day High with 8.06% Surge in Stock Price - Markets Mojo
Capricor Therapeutics (CAPR) Set to Announce Q4 Earnings - GuruFocus
CAPR Stock Surged 17% Today — What’s Fueling The Rally? - Stocktwits
Capricor Therapeutics Hits Day High with Strong 9.04% Intraday Surge - Markets Mojo
FDA resumes review of Capricor’s cell therapy deramiocel - The Pharma Letter
Capricor Therapeutics Hits Day High with Strong 9.78% Intraday Surge - Markets Mojo
Capricor Therapeutics Opens with 10.29% Gain, Outperforming S&P 500's 0.83% Rise - Markets Mojo
FDA resumes review of Capricor’s Deramiocel for DMD treatment By Investing.com - Investing.com Canada
Capricor Therapeutics (CAPR) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
H.C. Wainwright Maintains Buy on Capricor Therapeutics, Inc. (CAPR) Mar 2026 - Meyka
Why Capricor Therapeutics (CAPR) Is Up 29.3% After FDA Resumes Review of Deramiocel BLA - simplywall.st
Capricor Therapeutics (CAPR) Surges as FDA Reviews Key Therapy - GuruFocus
What's Going On With Moderna, Capricor, Other Biotech Stocks On Monday? - Sahm
Capricor Therapeutics Inc expected to post a loss of 54 cents a shareEarnings Preview - TradingView
Capricor Therapeutics Rises as FDA Lifts Complete Response Letter, Resumes Review - marketscreener.com
Capricor Therapeutics Sees Surge in Trading Volume - National Today
Capricor Therapeutics (NASDAQ:CAPR) Sees Strong Trading VolumeShould You Buy? - MarketBeat
Jones Trading reiterates Capricor stock Buy on FDA review resumption By Investing.com - Investing.com Canada
HC Wainwright Reiterates Buy Rating for Capricor Therapeutics (C - GuruFocus
Capricor Advances Deramiocel BLA Review for Duchenne DMD - TipRanks
Capricor Therapeutics stock surges on FDA BLA review resumption - Investing.com
Capricor Therapeutics (NASDAQ:CAPR) Given "Buy" Rating at HC Wainwright - MarketBeat
Nio, Zevra Therapeutics, Vertex Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday - Benzinga
Capricor resumes FDA BLA review for Deramiocel; PDUFA date set for Aug 22, 2026 - TradingView
FDA sets new Deramiocel PDUFA date for Capricor (NASDAQ: CAPR) - Stock Titan
Capricor Therapeutics Stock Jumps As FDA Resumes Deramiocel Review - Benzinga
FDA Resumes Review of Capricor Therapeutics' (CAPR) Deramiocel A - GuruFocus
Capricorgains FDA reviews rejected cell therapy (CAPR:NASDAQ) - Seeking Alpha
Capricor Therapeutics Announces Establishment of New PDUFA Date for Deramiocel BLA - Bitget
Capricor Therapeutics, Inc. resumes Deramiocel BLA review as FDA sets August 22, 2026 deadline - Traders Union
Capricor Therapeutics Announces Resumption of FDA BLA Review for Deramiocel in Duchenne Muscular Dystrophy Following Positive Phase 3 Results - Quiver Quantitative
FDA resumes review of Duchenne drug Deramiocel, sets Aug. 22 deadline - Stock Titan
Xenon hits a ‘home run’ in epilepsy; FDA restarts review of Duchenne cell therapy - Yahoo Finance
Biotech Stocks Pop After CBER Chief ExitModerna (NASDAQ:MRNA) - Benzinga
Capricor Therapeutics (NASDAQ:CAPR) Shares Gap UpStill a Buy? - MarketBeat
Capricor Therapeutics Stock Rises Ahead of March 12 Update as FDA Watch on Duchenne Drug Builds - TechStock²
Capricor Therapeutics to Present Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Update on March 12 - The Manila Times
Capricor Therapeutics to Host Conference Call for Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026 - Quiver Quantitative
A Look At Capricor Therapeutics (CAPR) Valuation As FDA Tightens Expedited Approval Pathway - Sahm
Capricor Therapeutics Stock Pre-Market (+12%): 91-Day Insider Lock-Up Period Expires - Trefis
CAPR Stock In Spotlight As Investors Eye Next Week’s DMD Trial Data Showing Muscle And Cardiac Gains - Stocktwits
Capricor Therapeutics Poised for Breakthrough as HOPE-3 Trial Results Loom - timothysykes.com
Capricor Therapeutics (NASDAQ:CAPR) Trading Up 6.2%Here's What Happened - MarketBeat
Capricor Therapeutics Stock Jumps After-Hours As Retail Cheers Fresh FDA Attempt After Duchenne Therapy Rejection - Stocktwits
HOPE On The Horizon: Capricor To Present Deramiocel Data At The MDA Conference - RTTNews
CAPR Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Capricor (CAPR) Faces Challenges Amidst Stricter FDA Approval Pr - GuruFocus
Register: Aligning With the FDA on a Regulatory Pathway To Avoid Decision Day Surprises - BioSpace
(CAPR) Volatility Zones as Tactical Triggers - Stock Traders Daily
CAPR Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Capricor Therapeutics, Inc. (CAPR) Stock Analysis: Unpacking The 82% Potential Upside - DirectorsTalk Interviews
Capricor Therapeutics (CAPR) Schedule 13G: Suvretta reports 6.6% stake - Stock Titan
A Look At Capricor Therapeutics (CAPR) Valuation As Key Deramiocel Phase 3 Milestones Advance FDA Review - simplywall.st
Capricor Therapeutics Announces Late-Breaking Presentation at 2026 MDA Clinical and Scientific Conference - Bitget
Capricor Or Sarepta: Two DMD Stocks Enter A High-Stakes Week – Which One Has More Upside? - Asianet Newsable
1.76%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):